Not yet recruiting
Substudy to Evaluate the Potential Treatment Effect of the ABBV-7066 (risankizumab/ABBV-701) Combination Compared to Each Respective Monotherapy in Subjects with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis
2026-525960-16-00· Phase 2· AbbVie Deutschland GmbH & Co. KG· Source
Not yet recruiting
A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF)
(CALIBRATE-HF)
2025-525033-31-00· Phase 2· Cardurion Pharmaceuticals Inc.· Source
Recruiting
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
NCT07697456· Phase 2· AbbVie· Source
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer
NCT07457164· Phase 2· Antev Ltd.· Source
Enrolling by invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294· Phase 2· Spyre Therapeutics, Inc.· Source
Recruiting
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
NCT07614776· Phase 3· Amgen· Source
Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
NCT07422480· Phase 3· Takeda· Source
Recruiting
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Recruiting
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292· Phase 3· Sanofi· Source
Recruiting
Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
2025-520982-39-00· Phase 3· Universita Degli Studi Di Milano Bicocca· Source
Active, not recruiting
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)
2025-521349-25-00· Phase 3· 4d Molecular Therapeutics Inc.· Source
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· Phase 3· Eli Lilly and Company· Source
Recruiting
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958· Phase 3· Syndax Pharmaceuticals· Source
Recruiting
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT07194850· Phase 2/3· argenx· Source
Recruiting
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
2024-518296-56-00· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
2024-512753-24-00· Phase 3· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336· Phase 3· AstraZeneca· Source
Recruiting
Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION)
2024-519521-37-01· Phase 2/3· Corxel Pharmaceuticals Co. Ltd.· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Recruiting
Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))
NCT06451913· Phase 4· Biocodex· Source
Active, not recruiting
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744· Phase 3· AbbVie· Source
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395· Phase 2· Spyre Therapeutics, Inc.· Source
Recruiting
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
NCT06711887· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285· Phase 3· Takeda· Source
Recruiting
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Recruiting
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
NCT06880770· Phase 3· Arrowhead Pharmaceuticals· Source
Active, not recruiting
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790· Phase 3· Arrowhead Pharmaceuticals· Source
Not yet recruiting
Toward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission
NCT06618937· Phase 4· Istituto Giannina Gaslini· Source
Recruiting
Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
NCT06488482· Phase 3· Uppsala University· Source
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542· Phase 2· AbbVie· Source
Active, not recruiting
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source
Active, not recruiting
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228· Phase 3· AbbVie· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06257875· Phase 2· AbbVie· Source
Recruiting
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
NCT06262438· Phase 2· Princess Maxima Center for Pediatric Oncology· Source
Active, not recruiting
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473· Phase 3· Sanofi· Source
Active, not recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967· Phase 3· AbbVie· Source
Recruiting
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842· Phase 3· Ipsen· Source
Active, not recruiting
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643· Phase 3· AbbVie· Source
Recruiting
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
2023-504999-25-00· Phase 3· Prinses Maxima Centrum voor Kinderoncologie B.V.· Source
Active, not recruiting
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182· Phase 3· AbbVie· Source
Active, not recruiting
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.
NCT05636176· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283· Phase 3· Bayer· Source
Active, not recruiting
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
NCT05135559· Phase 3· Novo Nordisk A/S· Source
Recruiting
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
NCT04804553· Phase 3· Amgen· Source
Recruiting
177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
NCT04903899· Phase 2· Jakob Stenman· Source
Recruiting
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
NCT04513639· Phase 2/3· Oslo University Hospital· Source
Showing 50 of 64.